Cantor Fitzgerald raised the firm’s price target on Cigna to $400 from $384 and keeps an Overweight rating on the shares following the quarterly results. Cantor sees the stock as undervalued and views Evernorth as a likely driver of earnings upside and is encouraged by its innovative positioning biosimilar market and EnCircleRx, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- CI Earnings: Cigna Rises on Strong Q1 Performance
- Cigna raises FY24 adjusted EPS view to $28.40 from $28.25, consensus $28.43
- Cigna reports Q1 adjusted EPS $6.47, consensus $6.22
- The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook
- Notable companies reporting before tomorrow’s open
